In this study, the molecular mechanisms of ovarian cancer development and promising therapeutic approaches were investigated. Genetic and epigenetic factors contributing to tumor cell transformation were analyzed, including mutations in BRCA1/2, TP53, and PTEN genes, as well as disruptions in DNA repair processes. Special attention was given to the role of signaling pathways such as PI3K/AKT/mTOR, WNT/β-catenin, and NOTCH in tumor progression. The study examined modern therapeutic strategies, including the use of PARP inhibitors, monoclonal antibodies, immunotherapy, and RNA interference. The findings confirm the relevance of further research into the molecular mechanisms of carcinogenesis to develop more effective personalized treatments for ovarian cancer.

ovarian cancer, molecular mechanisms, genetic mutations, signaling pathways, epigenetics, targeted therapy, PARP inhibitors, immunotherapy, personalized medicine.

Pellegrino B., Musolino A., Llop-Guevara A., Serra V., De Silva P., Hlavata Z., Sangiolo D., Willard-Gallo K., Solinas C. "Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review." Translational Oncology, 2020; 13(2): 410–422. DOI: 10.1016/j.tranon.2019.10.010.

Paijens S.T., Vledder A., de Bruyn M., Nijman H.W. "Tumor-infiltrating lymphocytes in the immunotherapy era." Cellular & Molecular Immunology, 2021; 18(4): 842–859. DOI: 10.1038/s41423-020-00565-9.

Plesca I., Tunger A., Müller L., Wehner R., Lai X., Grimm M.O., Rutella S., Bachmann M., Schmitz M. "Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy." Frontiers in Immunology, 2020; 11: 364. DOI: 10.3389/fimmu.2020.00364.

Andrikopoulou A., Zografos E., Apostolidou K., Kyriazoglou A., Papatheodoridi A.M., Kaparelou M., Koutsoukos K., Liontos M., Dimopoulos M.A., Zagouri F. "Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis." Frontiers in Oncology, 2022; 12. DOI: 10.3389/fonc.2022.1030786.

Tyulyandina A.S., Kolomiets L.A., Morkhov K.Yu., Nechushkina V.M., Pokataev I.A., Rumyantsev A.A., Tyulyandin S.A., Urmancheeva A.F., Khokhlova S.V. "Practical Recommendations for Drug Treatment of Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer." Malignant Tumors, 2022; 12(3s2-1): 198–211. DOI: 10.18027/2224-5057-202212-3s2-198-211.

Maksimov S.Ya., Guseinov K.D. "Targeted Therapy for Ovarian Cancer." Practical Oncology.

Solopova E.N., Gavrilova N.E., Kuznetsova E.B., Levshin V.F., Mikhailov V.V., Mikhailova N.A., Novikova E.G., Petrova I.V., Safronova I.D., Sidorova I.S., Sidorova M.V., Solovyova N.I., Fedorova E.V., Shevchenko A.A. "Ovarian Cancer: Modern Approaches to Classification, Diagnosis, Staging, and Differentiated Management Strategies." Journal of Obstetrics and Women's Diseases.

Adamyan L.V., Aksel E.M., Akulenko L.V., Anufrieva K.S., Arapidi G.P., Artamonova E.V., Ashrafyan L.A., Braga E.A., Gershtein E.S., Govorun V.M., Gulyaeva L.F., Zhardania K.I., Ivanov Yu.D., Kadagidze Z.G., Kazubskaya T.P., Kaysheva A.L., Karseladze A.I., Kechin A.A., Kolomiets L.A., Kondakova I.V., et al. "Ovarian Cancer: Fundamental and Clinical Studies." OAO Meditsina Publishing House, 2021. ISBN: 978-5-6045698-9-4.

Pokataev I.A., Tyulyandin S.A. "The Role of Targeted Drugs in Ovarian Cancer Therapy." Effective Pharmacotherapy. Oncology, Hematology, and Radiology, No. 3.

Asaturova A. "Molecular Genetics of Ovarian Cancer."

Banerjee S., Kaye S.B. "New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential." Clinical Cancer Research, 2013; 19(5): 961–968. DOI: 10.1158/1078-0432.CCR-12-2273.

Lheureux S., Braunstein M., Oza A.M. "Epithelial ovarian cancer: Evolution of management in the era of precision medicine." CA: A Cancer Journal for Clinicians, 2019; 69(4): 280–304. DOI: 10.3322/caac.21559.

Ledermann J.A., Raja F.A., Fotopoulou C., Gonzalez-Martin A., Colombo N., Sessa C. "Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up." Annals of Oncology, 2013; 24(suppl_6): vi24–vi32. DOI: 10.1093/annonc/mdt333.